CJC-1295 – NO DAC – (5mg)
Table of Contents
Quickstart Highlights
CJC-1295 NO DAC (also known as Mod GRF (1-29)) is a short-acting GHRH analogue used in research to study pulsatile GH secretion. Because its half-life is ~30 minutes, protocols typically use either a single bedtime dose (0.2–0.3 mg) or multiple small pulses across the day.
- Two recognized approaches : 1× nightly (200–300 mcg) or 2–3× daily (100–200 mcg per injection)
- Reconstitution: Use up to 3.0 mL bacteriostatic water (max vial capacity) for practical syringe units
- Units math (3.0 mL) : 100 mcg = 6 units (0.06 mL); 200 mcg = 12 units (0.12 mL)
- Storage : Lyophilized at ≤−20 °C (preferably −80 °C for long-term); after reconstitution, 2–8 °C
- For Research Use Only : Not for human or veterinary use
Dosing & Reconstitution Guide
Educational guide for reconstitution and dosing protocol
Standard / Gradual Approach (Reconstitute 3.0 mL → 1.67 mg/mL)
| PHASE | DOSAGE (MCG) | UNITS (PER INJECTION) |
|---|---|---|
| Weeks 1–4 | 200 mcg × 1 injection at bedtime | 12 units (0.12 mL) |
| Weeks 5–8 | 250 mcg × 1 injection at bedtime | 15 units (0.15 mL) |
| Weeks 9–12 (Optional) | 300 mcg × 1 injection at bedtime | 18 units (0.18 mL) |
Why 3.0 mL? Using the maximum vial volume improves measuring accuracy and keeps most per-injection volumes at or above ~10 units on U-100 insulin syringes.
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly along the vial wall; avoid foaming.
- Gently swirl; do not shake vigorously.
- Label date/time of reconstitution; store at 2–8 °C and protect from light.
Advanced / Aggressive Approach (Reconstitute 3.0 mL → 1.67 mg/mL)
| PHASE | DOSAGE (MCG) | UNITS (PER INJECTION) |
|---|---|---|
| Weeks 1–4 | 100 mcg × 2 injections (AM & PM) | 6 units (0.06 mL) |
| Weeks 5–8 | 100 mcg × 3 injections (AM / Mid-day / PM) | 6 units (0.06 mL) |
| Weeks 9–12 (Optional) | 200 mcg × 2 injections (AM & PM) | 12 units (0.12 mL) |
- Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- Slowly inject the water to reduce foaming and peptide agitation.
- Gently roll/swirl the vial—no vigorous shaking.
- Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
Protocol Overview
Summary of recognized research schedules for CJC-1295 NO DAC (Mod GRF 1-29).
- Goal : Study pulsatile GH release via GHRH receptor agonism
- Schedule : Nightly 0.2–0.3 mg or 2–3 micro-pulses/day (100–200 mcg each)
- Reconstitution : Up to 3.0 mL (max vial capacity) to improve measurement precision
- Concentration @ 3.0 mL : ~1,667 mcg/mL (100 mcg = 0.06 mL; 200 mcg = 0.12 mL)
- Cycle Length : Commonly 8–12 weeks; extend as needed for study design
Dosing Protocol
Keep daily timing consistent. For multi-pulse schedules, space injections (e.g., morning / mid-day / pre-bed).
- Standard Nightly : 200–300 mcg once at bedtime (12–18 units at 3.0 mL)
- Advanced Pulses : 100 mcg 2–3× daily (6 units per injection at 3.0 mL); optional 200 mcg 2× daily (12 units)
- Measuring Tip : If a dose remains <10 units even at 3.0 mL, use 50- or 30-unit syringes
- Compatibility : Researchers often explore GHRH+GHS combinations in the literature; this guide does not recommend any stacks for use
Storage Instructions
Follow general peptide handling best practices.
- Lyophilized : Store tightly capped at ≤−20 °C (preferably −80 °C for long-term), dry and dark
- Reconstituted :2–8 °C; avoid repeated freeze-thaw by aliquoting if long-term storage is needed
- Bring vial to room temperature before opening to limit moisture ingress
Suppilies Needed
Estimate based on the Standard nightly approach (200–300 mcg once daily). One vial contains 5 mg.
- Peptide Vials (5 mg each) :
• 8 wks ≈ 3–4 vials (11.2–16.8 mg)
• 12 wks ≈ 4–6 vials (16.8–25.2 mg)
• 16 wks ≈ 5–7 vials (22.4–33.6 mg)
- Insulin Syringes (U-100): Nightly × 8/12/16 wks ≈ 56 / 84 / 112 syringes (more if following multi-pulse schedules)
- Bacteriostatic Water:10 mL vials (quantity per cycle as needed)
- Alcohol Swabs: 1 box
Important Notes
- Rotate injection sites; use new sterile syringes
- Track dates, volumes, and concentrations in a lab notebook for reproducibility
- Observe and document any unexpected observations; discontinue experiments if contamination is suspected
- Compliance : For research use only. Not for human or veterinary use. No medical advice is provided.
How This Works
CJC-1295 NO DAC (Mod GRF 1-29) is a 29-aa GHRH analogue with four substitutions that increase resistance to enzymatic cleavage, extending activity compared to native GRF(1-29). It binds the GHRH receptor on pituitary somatotrophs to stimulate pulsatile GH release and downstream IGF-1 production. Short half-life (~30 min) supports multi-pulse paradigms; literature also explores synergistic responses when GHRH analogues are combined with GHSR agonists (e.g., GHRP-2, Ipamorelin) in controlled settings.
- Tetrasubstitution : key aa changes improve stability versus native GRF(1-29)
- Pulsatility : preserves physiologic GH pulse patterns observed in studies
- Contrast with DAC version : DAC conjugation extends half-life to days and supports weekly dosing (different protocol)
Potential Research Observations & Considerations
Reported in research and clinical literature exploring GHRH analogues and GH secretagogues:
- Pulsatile GH/IGF-1 dynamics with dosing paradigms that respect physiologic rhythms
- Commonly reported mild effects: injection-site irritation, flushing, transient fatigue or dizziness
- Studies of combined secretagogues note possible endocrine cross-talk; designs should monitor relevant analytes
Lab Planning Tips
- Define sampling windows (e.g., pre-/post-dose GH/IGF-1 timepoints) before starting
- Standardize dosing relative to meals and time of day to reduce variability
- Document storage conditions, batch/lot, and reconstitution details for QC traceability
Injection Technique
General laboratory handling guidance for subcutaneous administration in research settings:
- Clean vial stopper and intended site with alcohol swabs; allow to dry
- Insert needle at 45–90° into subcutaneous tissue; inject slowly
- Dispose of sharps per local regulations; record dose, time, and site
Recommended Source
We recommend Go Alpha Labs for high-purity research peptides.
Why Go Alpha Labs?
- Independent lab verification targeting ≥99% purity
- ISO-aligned QC processes and batch traceability
- Reliable fulfillment and researcher-focused support
Important Note:
For Research Use Only. Not for human or veterinary use. This page is an educational resource and does not provide medical advice.
References
| Source | Link |
|---|---|
| Soule S, et al. – Incorporation of D-Ala2 in GHRH-(1-29)-NH2 increases half-life and decreases metabolic clearance (J Clin Endocrinol Metab, 1994) | View Source |
| Izdebski J, et al. – New potent hGH-RH analogues with increased resistance to enzymatic degradation (J Pept Sci, 2002) | View Source |
| Frohman LA, et al. – Rapid enzymatic degradation of GHRH by plasma in vitro and in vivo (J Clin Invest, 1986) | View Source |
| Teichman SL, et al. – Prolonged stimulation of GH & IGF-I by CJC-1295 (DAC) in adults; PK t½ ~6–8 days (JCEM, 2006) | View Source |
| Ionescu M, et al. – CJC-1295 enhances pulsatile GH secretion in humans (JCEM, 2006) | View Source |
| Walker RF. – Sermorelin: approach to adult-onset GH deficiency; physiology & pulsatility (Integr Med, 2006) | View Source |
| Sinha DK, et al. – Beyond the androgen receptor: GHS/GHRH combinations incl. 100 µg TID schedules (World J Mens Health, 2020) | View Source |
| Sigalos JT, et al. – Growth hormone secretagogue treatment in hypogonadal men on TTh (Andrology, 2017) | View Source |
| Bowers CY, et al. – Synergy of GHRH + GHRP-2 on pulsatile GH in older adults (JCEM, 2004) | View Source |
| NCBI Bookshelf. – Normal Physiology of Growth Hormone in Adults (2019) | View Source |
| Sigma-Aldrich. – Handling & Storage Guidelines for Peptides and Proteins | View Source |
| Sigma-Aldrich. – Synthetic Peptide Handling & Storage Protocol | View Source |
| ScienceDirect Topic – Sermorelin – overview of indications, dosing context | View Source |
| Schally AV, et al. – Development of GHRH analogues; stability-enhancing substitutions (Front Endocrinol Rev, 2024) | View Source |
| RxList. – Sermorelin Acetate – adult dosing references (0.2–0.3 mg qHS) | View Source |